LexDanaLexDanabeta
Inventor

Yoshihiro Kawaoka

Inventor
Middleton, WI, US

Overview

47→
Patents
2005–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 47 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes30%
C12NMicroorganisms or enzymes29%
C07KPeptides17%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations13%
Y02ATechnologies for adaptation to climate change4%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture2%
C12YEnzymes2%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
PatentTitleYear
11,046,934Mutations that confer genetic stability to additional genes in influenza viruses202111,007,262Vaccines comprising mutant attenuated influenza viruses202110,808,229High titer recombinant influenza viruses with enhanced replication in vero cells202010,633,422Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA202010,513,692Influenza viruses with mutant PB2 segment as live attenuated vaccines201910,494,613Generation of infectious influenza viruses from virus-like particles201910,369,210Cells for producing influenza virus and method for producing influenza virus201910,358,630Recombinant influenza vectors with tandem transcription units201910,246,686Influenza virus replication for vaccine development201910,172,934High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs201910,130,697Vaccines comprising mutant attenuated influenza viruses201810,119,124Influenza M2 protein mutant viruses as live influenza attenuated vaccines201810,059,925High titer recombinant influenza viruses with enhanced replication in vero cells201810,053,671Mutations that confer genetic stability to additional genes in influenza viruses20189,950,057High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs20189,926,535'High titer recombinant influenza viruses for vaccines'20189,890,363'Influenza virus replication for vaccine development'20189,580,693'Recombinant influenza viruses for vaccines and gene therapy'20179,474,798'Influenza M2 protein mutant viruses as live influenza attenuated vaccines'20169,254,318'High titer recombinant influenza viruses for vaccines'20169,222,118'Screen for inhibitors of filovirus and uses therefor'20159,157,096'Reassortant influenza viruses for vaccines'20159,109,013'High titer recombinant influenza viruses with enhanced replication in vero cells'20159,101,653'Influenza viruses with mutant PB2 gene segment as live attenuated vaccines'20159,023,603'Recombinant influenza viruses for vaccines and gene therapy'20158,900,595'Filovirus vectors and noninfectious filovirus-based particles'20148,877,448'Method of making recombinant influenza virus'20148,877,209'Recombinant influenza vectors with tandem transcription units'20148,859,208'System producing infectious recombinant influenza virus'20148,715,940'Method of making recombinant influenza virus'20148,679,819'Mutant cells with altered sialic acid'20148,597,661'Neuraminidase-deficient live influenza vaccines'20138,507,247'Influenza A virus with attenuating mutations in NS2 protein'20138,475,806'High titer recombinant influenza viruses for vaccines and gene therapy'20138,465,960'Influenza B viruses with reduced sensitivity to neuraminidase inhibitors'20138,298,805'Signal for packaging of influenza virus vectors'20128,163,523'Cell-based systems for producing influenza vaccines'20128,057,806'Viruses comprising mutant ion channel protein'20118,043,856'Adenoviral vectors for influenza virus production'20117,968,101'Recombinant influenza vectors with tandem transcription units'20117,723,094'Recombinant influenza vectors with a polII promoter and ribozymes for vaccines and gene therapy'20107,588,769'Viruses encoding mutant membrane protein'20097,585,657'Signal for packaging of influenza virus vector'20097,226,774'Signal for packaging of influenza virus vectors'20077,211,378'Filovirus vectors and noninfectious filovirus-based particles'20077,176,021'Mutant cells with altered sialic acid'20076,872,395'Viruses comprising mutant ion channel protein'2005

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2005–2020Patents assigned to WISCONSIN ALUMNI RES FOUND (30)· patent assignee history
2005–2014Based in Madison, WI, US· patent location history
2007–2021Based in Middleton, WI, US· patent location history
2009–2014Based in Middletown, WI, US· patent location history
2011–2018Patents assigned to KAWAOKA YOSHIHIRO (20)· patent assignee history
2012–2015Patents assigned to NEUMANN GABRIELE (8)· patent assignee history
2015–2016Patents assigned to HORIMOTO TAISUKE (2)· patent assignee history
2018–2021Patents assigned to WISCONSIN ALUMNI RES FOUNDATION WARF (16)· patent assignee history
2019Based in Minato-ku, JP· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
WISCONSIN ALUMNI RES FOUND302005–2020
KAWAOKA YOSHIHIROself202011–2018
WISCONSIN ALUMNI RES FOUNDATION WARF162018–2021
NEUMANN GABRIELE82012–2015
HORIMOTO TAISUKE22015–2016
Locations
LocationPatentsSpan
Middleton, WI, US392007–2021
Madison, WI, US52005–2014
Middletown, WI, US22009–2014
Minato-ku, JP12019